Premium
MicroRNA‐335‐5p and ‐3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance
Author(s) -
Martin Elizabeth C.,
Conger Adrienne K.,
Yan Thomas J.,
Hoang Van T.,
Miller David F. B.,
Buechlein Aaron,
Rusch Douglas B.,
Nephew Kenneth P.,
CollinsBurow Bridgette M.,
Burow Matthew E.
Publication year - 2017
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1002/1873-3468.12538
Subject(s) - tamoxifen , estrogen receptor alpha , microrna , alpha (finance) , cancer research , estrogen receptor , estrogen receptor beta , chemistry , estrogen , endocrinology , medicine , pharmacology , microbiology and biotechnology , biology , biochemistry , breast cancer , cancer , gene , construct validity , nursing , patient satisfaction
microRNAs (miRNAs) are small noncoding RNA molecules involved in the regulation of gene expression and play critical roles in human malignancies. Next‐generation sequencing analysis of the MCF‐7 breast cancer cell line overexpressing miR‐335‐5p and miR‐335‐3p demonstrated that the miRNA duplex repressed genes involved in the ERα signaling pathway, and enhanced resistance of MCF‐7 cells to the growth inhibitory effects of tamoxifen. These data suggest that despite its conventional role in tumor suppression, the miR‐335 transcript can also play an oncogenic role in promoting agonistic estrogen signaling in a cancerous setting.